The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Tyler F. Stewart ...

The FDA granted accelerated approval to Boehringer Ingelheim’s Hernexeos for first-line HER2-mutant NSCLC following a 44-day ...

Detailed price information for Alx Oncology Holdings Inc (ALXO-Q) from The Globe and Mail including charting and trades.

This marks the first time a bispecific ADC has demonstrated a dual benefit in both PFS and OS within a phase 3 trial for TNBC ...

EMA validates Type II Variation marketing application for Enhertu as post-neoadjuvant treatment for patients with HER2 positive earlybreast cancer: Tokyo Saturday, February 21, 20 ...

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU ® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 ...

Emerging HER2-targeted therapies in lung cancer highlight the importance of real-world data and survival metrics for patient outcomes and treatment access. This episode offers a forward-looking ...

Pharmacists play a vital role in oncology, enhancing patient care through medication management, education, and support for novel therapies. This episode discusses the critical role of pharmacists in ...

RMAT status for KB707 enables expedited development with enhanced FDA engagement, supported by early KYANITE-1 activity and durability in heavily pretreated advanced/metastatic NSCLC. LungTIME-C01 ...

New targeted drugs transform HER2, ROS1 and ALK lung cancer care, boosting brain response and survival—while precision choices still matter. Bruna Pellini, MD, chief of Thoracic Oncology at Baptist ...

At a median follow-up of 53.5 months, the median PFS was 44.3 months with palbociclib and 29.1 months without. Adding palbociclib to standard maintenance therapy improves progression-free survival ...